Abstract Library

#4581 Clinical efficacy and safety of treatments for pancreatic and extra-pancreatic neuroendocrine tumours following treatment failure or disease progression: A systematic literature review

Introduction: Neuroendocrine tumours (NETs) are a diverse group of rare malignancies with few effective targeted treatments, highlighting a need for novel therapies.

Conference:

Presenting Author:

Authors: Karim E, Srirajaskanthan R, Bensegnor H, Chan K, Drane E,

Keywords: Neuroendocrine tumour, Systematic literature review,

#4576 Economic evidence for pancreatic and extra-pancreatic neuroendocrine tumours following treatment failure or disease progression: A systematic literature review

Introduction: Treatment failure and disease progression (PD) in neuroendocrine tumours (NETs), a rare group of malignancies, are common due to limited targeted treatments.

Conference:

Presenting Author:

Authors: Karim E, Sola-Morales O, Bensegnor H, Chan K, Drane E,

Keywords: Neuroendocrine Tumour, Systematic Literature Review, Economic,

#4564 Vasculogenic mimicry in neuroendocrine tumour across different primary sites

Introduction: Anti-angiogenesis treatments targeting VEGFRs, including Surufatinib and Cabozantinib, etc. showed better efficacy for pancreatic neuroendocrine tumours (NET) than NET of other primary sites. Recent clinical trial targeting tumour necrosis factor receptor-associated protein-1, leading to inhibition of vasculogenic mimicry (VM) showed contrary results to current VEGFRs-targeted treatments. However, VM of NET across different primary sites are yet to be understood.

Conference:

Presenting Author: Chen L

Authors: Chen L, Liang Y, Huang D, Ji S, Chen J,

Keywords: neuroendocrine tumour, pancreatic, extra-pancreatic, vasculogenic mimicry,

#4518 Efficacy and safety of cabozantinib (CABO) for advanced Grade 3 (G3) neuroendocrine tumours (NETs) after progression on prior therapy: Subgroup analysis of the phase III CABINET trial (Alliance A021602)

Introduction: Well-differentiated G3 NETs have been described as a distinct category recently, and randomised data regarding efficacy of therapy are scarce. In the phase 3 CABINET trial (NCT03375320), CABO significantly prolonged progression-free survival (PFS) compared with placebo (PB) in patients (pts) with advanced, previously treated, progressive well-differentiated extra-pancreatic NETs (epNETs) and pancreatic NETs (pNETs) of all grades (Chan et al., NEJM, 2024).

Conference:

Presenting Author: Strosberg J

Authors: Strosberg J, Zemla T, Geyer S, Pulsipher S, Behr S,

Keywords: cabozantinib, grade 3 neuroendocrine tumour, pancreatic neuroendocrine tumour, extra-pancreatic neuroendocrine tumour,

#4086 Prognostic significance of metabolomics clusters in extra-pancreatic NETs: Lung NET sub-analysis

Introduction: Metabolic flexibility is one of the key hallmarks of cancer and metabolites are the final products of this adaptation, reflecting the aberrant changes that support cancer cells proliferation and survival. In a previous metabolomics study carried out by our group, multiplatform untargeted metabolomic profiling (GC-MS, CE-MS and LC-MS) performed on plasma samples from 77 advanced G1-2 extra-pancreatic NET patients demonstrated that these patients have a distinct metabolomic profile, and identified methionine, porphyrin and tryptophan metabolism as the most relevant dysregulated pathways associated with the prognosis of NETs. Furthermore, a 3-metabolite signature was able to stratify patients in 3 distinct prognostic clusters, with cluster 3 associated with the best prognosis.

Conference:

Presenting Author:

Authors: La Salvia A, Lens-Pardo A, Carretero-Puche C, Capdevila J, Benavent M,

Keywords: metabolimics, prognostic biomarker, lung neuroendocrine tumor, metabolomic signature,